- Home
- RAPT vs CHRS Comparison
RAPT vs CHRS Comparison
Compare RAPT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- CHRS
- Stock Information
- Founded
- RAPT 2015
- CHRS 2010
- Country
- RAPT United States
- CHRS United States
- Employees
- RAPT N/A
- CHRS N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAPT Health Care
- CHRS Health Care
- Exchange
- RAPT Nasdaq
- CHRS Nasdaq
- Market Cap
- RAPT 117.5M
- CHRS 96.9M
- IPO Year
- RAPT 2019
- CHRS 2014
- Fundamental
- Price
- RAPT $0.79
- CHRS $1.12
- Analyst Decision
- RAPT Hold
- CHRS Strong Buy
- Analyst Count
- RAPT 7
- CHRS 4
- Target Price
- RAPT $5.00
- CHRS $5.38
- AVG Volume (30 Days)
- RAPT 1.1M
- CHRS 2.0M
- Earning Date
- RAPT 05-08-2025
- CHRS 05-08-2025
- Dividend Yield
- RAPT N/A
- CHRS N/A
- EPS Growth
- RAPT N/A
- CHRS N/A
- EPS
- RAPT N/A
- CHRS 0.25
- Revenue
- RAPT N/A
- CHRS $266,959,999.00
- Revenue This Year
- RAPT N/A
- CHRS N/A
- Revenue Next Year
- RAPT N/A
- CHRS $9.02
- P/E Ratio
- RAPT N/A
- CHRS $4.50
- Revenue Growth
- RAPT N/A
- CHRS 3.78
- 52 Week Low
- RAPT $0.79
- CHRS $0.66
- 52 Week High
- RAPT $8.58
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- RAPT 31.31
- CHRS 61.92
- Support Level
- RAPT $0.81
- CHRS $0.72
- Resistance Level
- RAPT $0.98
- CHRS $1.07
- Average True Range (ATR)
- RAPT 0.10
- CHRS 0.10
- MACD
- RAPT -0.03
- CHRS 0.04
- Stochastic Oscillator
- RAPT 7.72
- CHRS 95.19
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.